Nuo Therapeutics Inc  

(Public, OTCMKTS:NUOT)   Watch this stock  
Find more results for OTC:CMXI
0.265
0.000 (0.00%)
May 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.14 - 0.47
Open     -
Vol / Avg. 0.00/160,058.00
Mkt cap 33.32M
P/E     -
Div/yield     -
EPS -0.16
Shares 125.68M
Beta -1.09
Inst. own 0%
May 14, 2015
Q1 2015 Nuo Therapeutics Inc Earnings Call
May 13, 2015
Q1 2015 Nuo Therapeutics Inc Earnings Release
Apr 1, 2015
Full Year 2014 Nuo Therapeutics Inc Earnings Call
Mar 31, 2015
Full Year 2014 Nuo Therapeutics Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 150.48% -243.28%
Operating margin -232.94% -301.35%
EBITD margin - -229.69%
Return on average assets 19.67% -36.85%
Return on average equity 79.72% -88.28%
Employees 46 -
CDP Score - -

Address

207a Perry Pkwy Ste 1
GAITHERSBURG, MD 20877-2196
United States - Map
+1-240-4992680 (Phone)
+1-240-4992690 (Fax)

Website links

Description

Nuo Therapeutics, Inc., (Nuo Therapeutics) formerly Cytomedix, Inc. is a biomedical company. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company pioneers biodynamic therapies within the emerging opportunities of a changing healthcare landscape. Nuo Therapeutics' flagship product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. It is the only therapy that is FDA-cleared for use on ulcers and wounds of all types. Its commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. It has two distinct platelet rich plasma (PRP) devices, the AutoloGel TM System (relaunched as Aurix in October 2014) for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics markets.

Officers and directors

David E. Jorden CPA Acting Chief Financial Officer, Director
Age: 51
Martin P. Rosendale Chief Executive Officer, Director
Age: 56
Steven S. Shallcross CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 52
Peter A. Clausen Ph.D. Chief Science Officer
Dean Tozer Chief Commercial Officer
Lyle A. Hohnke Ph.D. Director
Age: 70
Joseph Del Guercio Acting Chairman of the Board
Age: 41
Stephen N. Keith M.D. Independent Director
Mark T. McLoughlin Independent Director
Age: 59
C. Eric Winzer Independent Director
Age: 56